HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SERA
Sera Prognostics, Inc.
SERA lost money over the past year, so it has no meaningful PE right now.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SERA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SERA's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SERA PE Valuation
SERA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SERA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SERA's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SERA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | +$0.11 |
| Q2 2026 | -$0.66 | +$0.19 |
| Q1 2026 | -$0.64 | +$0.30 |
| Q4 2025 | -$0.67 | +$0.32 |
| Q3 2025 | -$0.77 | +$0.22 |
| Q2 2025 | -$0.85 | +$0.13 |
| Q1 2025 | -$0.94 | +$0.13 |
| Q4 2024 | -$0.99 | +$0.17 |
SERA has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SERA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SERA on profitability, with a higher operating margin.
SERA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42K | +163% |
| Q2 2026 | $30K | +76% |
| Q1 2026 | $14K | -63% |
| Q4 2025 | $10K | -58% |
| Q3 2025 | $16K | -45% |
| Q2 2025 | $17K | -29% |
| Q4 2024 | $24K | -41% |
| Q3 2024 | $29K | -31% |
SERA's revenue is recovering but still below its 2023 peak: $42,000 last quarter, up 163% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -21160% | +34966 points |
| Q2 2026 | -33347% | +21477 points |
| Q1 2026 | -66857% | -42515 points |
| Q4 2025 | -89540% | -50278 points |
| Q3 2025 | -56125% | -25566 points |
| Q2 2025 | -54824% | -16269 points |
| Q1 2025 | -24342% | N/A |
| Q4 2024 | -39263% | -17682 points |
SERA's operating margin was −21160% last quarter, up 34965 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SERA on cash generation, producing positive trailing cash flow while its opponent burns cash.
SERA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.4M | -$843K |
| Q2 2026 | -$6.3M | -$573K |
| Q1 2026 | -$8.8M | -$1.2M |
| Q4 2025 | -$6.5M | -$182K |
| Q3 2025 | -$6.6M | +$432K |
| Q2 2025 | -$5.8M | +$181K |
| Q1 2025 | -$7.6M | -252% |
| Q4 2024 | -$6.3M | +$513K |
SERA has burned cash in almost every quarter: −$29M over the past year, against −$26M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SERA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SERA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +313K shares |
| 1 year | +2.6% | +1.3M shares |
| 3 years | +62% | +19.5M shares |
| 5 years | +66% | +20.3M shares |
| Available history | +180% | +32.7M shares |
SERA has 51M diluted shares, up 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SERA Net Leverage
SERA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SERA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 57.3 | Neutral |
SERA's weekly RSI is 46 (neutral) and its Stochastic is 57 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SERA PE vs Healthcare Sector
SERA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SERA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.06 | 3.9% below |
| 20 week MA | $2.05 | 3.4% below |
| 50 week MA | $2.29 | 14% below |
| 100 week MA | $2.97 | 33% below |
| 200 week MA | $4.19 | 53% below |
SERA is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SERA on returns for 2026, with the stronger performance.
SERA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.0 | $8.00 | -27% |
| 2022 | $8.00 | $1.60 | -80% |
| 2023 | $1.60 | $5.98 | +274% |
| 2024 | $5.98 | $8.00 | +34% |
| 2025 | $8.00 | $3.52 | -56% |
| 2026 YTD | $3.52 | $1.98 | -44% |
SERA's yearly returns have swung widely, from +274% in 2023 to −80% in 2022. It's down 44% so far in 2026.